Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04370587




Registration number
NCT04370587
Ethics application status
Date submitted
14/04/2020
Date registered
1/05/2020
Date last updated
29/08/2023

Titles & IDs
Public title
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Scientific title
A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Secondary ID [1] 0 0
CTIV1708
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumor 0 0
Melanoma 0 0
HNSCC 0 0
Sarcoma 0 0
Squamous Cell Carcinoma 0 0
NSCLC 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Cancer 0 0 0 0
Bone

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - T3011
Combination Product - T3011 + pembrolizumab

Experimental: Phase 1 - T3011 single agent dose escalation in participants with solid tumors

Experimental: Phase 2a Part 1 Arm A - RP2D T3011 single agent in participants with melanoma

Experimental: Phase 2a Part 1 Arm B - RP2D T3011 single agent in participants with other solid tumors

Experimental: Phase 2a Part 2 Arm C - RP2D T3011 + pembrolizumab in participants with NSCLC

Experimental: Rollover Arm - RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent


Other interventions: T3011
T3011 will be administered up to 4mL as an intratumoral injection given Q2W.

Combination Product: T3011 + pembrolizumab
T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Combination Product
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability of escalating doses T3011
Timepoint [1] 0 0
Up to 2 years from first dose of T3011
Primary outcome [2] 0 0
To determine the dose(s) of T3011 to be examined in Phase 2a
Timepoint [2] 0 0
Through the first two T3011 injections (approximately 28 days)
Primary outcome [3] 0 0
Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohorts
Timepoint [3] 0 0
Up to 2 years from first dose of T3011
Primary outcome [4] 0 0
Characterize the safety and tolerability of T3011 in combination with pembrolizumab
Timepoint [4] 0 0
Up to 2 years from first dose of T3011
Primary outcome [5] 0 0
Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 alone
Timepoint [5] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [1] 0 0
Overall response rate (ORR)
Timepoint [1] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [2] 0 0
Disease control rate (DCR)
Timepoint [2] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [3] 0 0
Duration of response (DOR)
Timepoint [3] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [4] 0 0
Durable response (DR)
Timepoint [4] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [5] 0 0
Progression-free survival (PFS)
Timepoint [5] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [6] 0 0
Overall Survival (OS)
Timepoint [6] 0 0
Up to 1 year after last dose of T3011
Secondary outcome [7] 0 0
Presence of neutralizing antibodies of anti-PD-1 antibody for antidrug antibodies (ADAs) development
Timepoint [7] 0 0
Up to 2 years from first dose of T3011
Secondary outcome [8] 0 0
Presence and frequency of T3011 in injection site swab, saliva, and urine
Timepoint [8] 0 0
Up to 2 years from first dose of T3011

Eligibility
Key inclusion criteria
Key

1. Age 18 years or older.

2. Disease progression after standard of care (SOC) therapy or in the opinion of

3. The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 -
Histologically or pathologically confirmed locally recurrent or metastatic advanced
malignancy.

Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must
have received no more than 3 prior regimens for advanced or metastatic disease.

ii. Arm B - locally recurrent or metastatic HNSCC. It must also meet the following
criteria: 1) Disease progression to platinum-containing chemotherapy; 2) Failure to
anti-PD-1/PDL1 blockade after receiving at least 2 doses alone or in combination.

iii. Arm C - Sarcoma. Participants must have received no more than three lines of
prior anti-cancer therapies.

iv. Arm D - locally recurrent or metastatic cSCC. Participants must have received no
more than 3 prior regimens for advanced or metastatic disease.

Phase 2a Part 2 i.v. Arm E - Histologically or pathologically confirmed NSCLC that is
advanced or recurrent, without EGFR mutation or ALK rearrangement. Participants must
have received at least one line but no more than three lines of prior anti-cancer
therapies.

4. Measurable disease per RECIST version 1.1.

5. Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the
opinion of the investigator.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

7. Life expectancy > 12 weeks.

8. Demonstrate adequate organ function as defined by acceptable laboratory testing
results.

9. Women of child-bearing potential (WCBP) and men must agree to use adequate
contraception prior to study entry, while on study treatment, and for six months after
receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to
W1D1.

10. Last dose of previous anticancer therapy = 21 days, radiotherapy > 21 days, or
surgical intervention > 21 days prior to the first dose of T3011.

11. Recovered from all prior anticancer therapy toxicities.

12. Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of
Assessments.

13. Capable of understanding and complying with protocol requirements.

14. Signed and dated institutional review board/independent ethics committee-approved
informed consent form before any protocol-directed screening procedures are performed.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Have only uninjectable tumors..

2. Patients with injectable tumors impinging upon major airways or blood vessels.

3. HNSCC only: Prior re-irradiation field containing carotid artery.

4. Greater than 3 distant metastatic lymph node regions and/or metastatic lesions or the
largest distant metastases with a diameter of more than 3 cm (non-sarcoma)/5 cm
(sarcoma) unless the lesion is to be injected.

5. Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or
gene therapy.

6. Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy
related non-infectious pneumonitis/interstitial lung disease.

7. Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.

8. Requires continued concurrent therapy with any drug active against HSV.

9. Live vaccines, attenuated vaccines within 4 weeks prior to initiation of study
treatment (participants vaccinated with inactivated vaccines can be enrolled.

10. Primary or acquired immunodeficient states.

11. Pregnant or lactating.

12. Prior organ transplantation.

13. Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive
serological test at Screening within 14 days of dosing with T3011.

14. Active autoimmune disease or medical conditions requiring chronic steroid or
immunosuppressive therapy within 4 weeks prior to first administration of study
treatment.

15. History of or current central nervous system metastases.

16. History of seizure disorders within 6 months of Screening.

17. Active oral or skin herpes lesion at Screening.

18. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis
requiring treatment with systemic steroids.

19. Congestive heart failure, active coronary artery disease, unevaluated new onset angina
within 3 months or unstable angina, or clinically significant cardiac arrhythmias.

20. History of allergic reactions attributed to compounds of similar biological
composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.

18. Active infection with SARS-CoV-2 virus. 21. Participants with moderate to large amount
of pleural effusion, ascites or pericardial effusion who need drug or medical intervention.

22. Other systemic conditions or organ abnormalities that, in the opinion of the
investigator, may interfere with the conduct and/or interpretation of the current study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/09/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/10/2025
Actual
Sample size
Target
64
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Southern Oncology - Bedford Park
Recruitment hospital [2] 0 0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Recruitment hospital [3] 0 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment postcode(s) [2] 0 0
- Frankston
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Pennsylvania
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
United States of America
State/province [5] 0 0
Virginia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ImmVira Pharma Co. Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of
intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients
with advanced or metastatic solid tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04370587
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
ImmVira Pharma Co. LTD
Address 0 0
Country 0 0
Phone 0 0
781-718-5121
Fax 0 0
Email 0 0
clinicaltrials@immviragroup.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04370587